Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

30.62
-1.0200-3.22%
Post-market: 30.620.00000.00%17:07 EDT
Volume:1.37M
Turnover:42.10M
Market Cap:3.69B
PE:-10.11
High:31.77
Open:31.14
Low:30.00
Close:31.64
Loading ...

BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters
·
13 Mar

Avidity Biosciences initiated with an Outperform at BMO Capital

TIPRANKS
·
12 Mar

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Benzinga
·
11 Mar

Avidity Biosciences Is Maintained at Buy by B of A Securities

Dow Jones
·
11 Mar

Arrowhead announces topline results from ARO-C3 trial

TIPRANKS
·
10 Mar

Avidity Biosciences Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Avidity Biosciences initiated with an Outperform at Scotiabank

TIPRANKS
·
07 Mar

Avidity Biosciences (RNA) Gets a Buy from TD Cowen

TIPRANKS
·
06 Mar

Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Business Wire
·
06 Mar

Circio’s Circular RNA Platform Shows Promising Advancements

TIPRANKS
·
05 Mar

Circio Holding ASA Gains Media Attention for Circular RNA Innovations

TIPRANKS
·
03 Mar

Avidity Biosciences (RNA) Gets a Buy from Wells Fargo

TIPRANKS
·
02 Mar

Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
01 Mar

Avidity Biosciences Advances RNA Therapeutics for Rare Diseases

TIPRANKS
·
01 Mar

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

PR Newswire
·
28 Feb

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
28 Feb

RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk

MT Newswires Live
·
28 Feb

Avidity Biosciences: Promising Drug Pipeline and Potential Approval for DMD44 Drive Buy Rating

TIPRANKS
·
28 Feb

Avidity Biosciences price target lowered to $57 from $63 at Barclays

TIPRANKS
·
28 Feb

Avidity Biosciences (RNA) Gets a Buy from Barclays

TIPRANKS
·
28 Feb